News - Page 12 of 14 - Leukaemia Care

4th July 2018

Charity partnership with Kidderminster Harriers FC

We're over the moon to announce that we've been selected as the charity partner for Kidderminster Harriers FC this July through to September!

4th July 2018

Gamers raise over £500 for Leukaemia Care!

Over one weekend a group of gamers from the Stallion Streaming Community (SSC) turned their passion of gaming into a fundraising event for Leukaemia Care.

29th June 2018

European Medicines Agency issue positive opinion on CAR-T Therapy

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has today issued a positive opinion on the use of two new CAR-T therapies in Europe.

26th June 2018

Kettering man to rally online gamers for leukaemia charity

Gaming for good in aid of Leukaemia Care

11th June 2018

Scottish Medicines Consortium (SMC) recommended the use of inotuzumab ozogamicin

The Scottish Medicines Consortium (SMC) issues restricted recommendation for use of inotuzumab ozogamicin in the treatment of adults with relapsed/refractory acute lymphoblastic leukaemia (ALL) in Scotland.

11th June 2018

Scottish Medicines Consortium (SMC) recommend the use of midostaurin for adult acute myeloid leukaemia patients

Scotland receives a positive recommendation by the SMC for the use of FLT3-mutation-positive targeted therapy midostaurin in first-line AML treatment.

16th May 2018

Ibrutinib for chronic lymphocytic leukaemia (CLL) patients.

Today a letter has been written to the editor at regarding treatment for chronic lymphocytic leukaemia (CLL) patients.

4th May 2018

NICE approves midostaurin for treating Acute Myeloid Leukaemia (AML)

NICE have issued their Final Appraisal Document (FAD) approving the use of midostaurin in first-line treatment of FLT3-mutation-positive acute myeloid leukaemia (AML).

4th May 2018

NICE approves arsenic trioxide for use in acute promyelocytic leukaemia (APL) treatment

NICE have today (Friday 4 May) recommended the use of arsenic trioxide in the treatment of acute promyelocytic leukaemia (APL).

4th May 2018

Brentuximab Vedotin becomes the first drug under the new Cancer Drugs Fund (CDF) to be approved for routine commissioning by the NHS.

Brentuximab vedotin (manufactured by Takeda and also known as Adcetris®) has been available via the Cancer Drugs Fund since 2013. Today it has been approved by NICE (the National Institute for Health and Care Excellence) for routine use within the NHS.